Finance

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases1. A […]

After a disappointing start to the year, the last few months have seen a boost to fundraising for UK biotech companies. DDW’s Diana Spencer unpacks the Q3 figures and annual predictions from the BioIndustry Association1.  While 2021 was the highest year on record for investments into UK biotech and life sciences companies, it looks unlikely […]

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships have been forged and renewed to shed light on neuropsychiatric disorders, oncology and cystic fibrosis. Meanwhile, Ochre Bio successfully raised […]

Three international life sciences start-ups have received investment from the BioInnovation Institute (BII).   The three new ventures were chosen as part of the BII’s focus on developing scientific initiatives across the therapeutics and health tech space.  The companies, Sevenless Therapeutics, VEIL.AI and Myopax, will receive €1.3 million and will form part of the BII’s community […]

BioXcel Therapeutics has raised $260 million in funding to support the commercial activities of its proprietary, orally dissolving film formulation IGALMI. Previously known as BXCL501, IGALMI is an orally dissolving film formulation of dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The funding comes […]

DDW Deputy Editor Reece Armstrong recently attended the Invest in Toulouse Virtual Round Table to find out how the city is establishing itself as a place of exciting research in the healthcare sectors.   Hosted by Jean-Claude Dardelet, the city’s Deputy Mayor, the roundtable examined how Toulouse is becoming an international destination for companies across various […]

Global drug development consultancy Boyds has reported strong financial growth following a two-year strategy to expand its business.  Boyds saw an increase of over 20% year-on-year in annual revenue in the wake of increased demand for drug development expertise across the UK, US, and Europe.  In particular, the company recorded growth in US revenue which […]

Cell therapy company Bone Therapeutics has announced it is shifting its R&D activities towards its most advanced clinical asset, the allogenic cell therapy platform, ALLOB.   The platform    ALLOB is an off-the-shelf allogenic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors. […]

Clinical pharmatech company Exscientia’s Series C financing round was completed with investment of $30 million from BlackRock, which will accelerate its AI drug discovery platform and pipeline. Blackrock funds joined Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital in the investment $100 million round. New capital will be used to support Exscientia’s platform […]